Skip to main content
Top
Published in: Breast Cancer Research 1/2000

01-03-2000 | Oral presentation

Two molecular cytogenetic views of breast cancer

Authors: J Gray, K Chin, C Collins, P Yaswin, G Nonet, D Kowbel, W-L Kuo, E Garcia, C Ortiz de Solorzano, D Knowles, S Lockett, M Bissell, V Weaver, D Pinkel, D Albertson, A-L Børresen-Dale, F Waldnian

Published in: Breast Cancer Research | Special Issue 1/2000

Login to get access

Excerpt

This talk will present two views of genome evolution in human breast cancers using fluorescence in situ hybridization (FISH) and comparative genomic hybridization (CGH). FISH with chromosome-specific probes applied to thick tissue sections from tumors at several stages of progression reveals a remarkable level of cell-to-cell variability beginning with hyperplasia and increasing with increasing grade. These studies also demonstrate significant genomic evolution, including formation of polyploid nuclei within a single sample, suggesting a very high rate of genomic instability. These phenomena also were observed in vitro in few-cell clones established from breast cancer cell lines. Paradoxically, CGH analyses of 'average' genome copy number changes show relatively slow overall rates of evolution in vitro and in vivo. CGH karyotypes for breast cancer cell lines change relatively slowly as long as the environment remains constant. Likewise, CGH karyotypes of pairs of primary vs. metastatic or in situ vs. invasive breast tumors from the same patient are usually quite similar, suggesting a relatively slow rate of evolution. Possible explanations for this paradox will be discussed. …
Metadata
Title
Two molecular cytogenetic views of breast cancer
Authors
J Gray
K Chin
C Collins
P Yaswin
G Nonet
D Kowbel
W-L Kuo
E Garcia
C Ortiz de Solorzano
D Knowles
S Lockett
M Bissell
V Weaver
D Pinkel
D Albertson
A-L Børresen-Dale
F Waldnian
Publication date
01-03-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr195

Other articles of this Special Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine